Indeed, increased plasma ACE2 levels from early to late stages of the disease have been reported in severe COVID-19 patients (24), and an upward trajectory of circulating ACE2 is associated with an elevated risk of mortality and organ injuries (25). This evidence concerns the gene ACE2 and COVID-19.